Second Generation Phenylthiazole Antibiotics for Treatment of MRSA
Researchers at Purdue University have developed second generation Phenylthiazole antibiotics with enhanced pharmacokinetic properties. After synthesis, tuning, and proper treatment of the substances, one of the compounds showed significant improvement in in-vitro anti-MRSA potency. The rapid elimination of bacterial cells was achieved. This series has improved pharmacokinetic properties compared to the first generation with a better safety profile.
Improved pharmacokinetic propertiesRapid elimination of bacterial cellsSignificant improvement in in-vitro anti-MRSA potency
MRSA treatmentTreatment of other 'superbugs'Antibiotic development
Mark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology
United States
None
美國
